The DOI matches its Crossref record.
Superiority of Alternating Non-Cross-Resistant Chemotherapy in Extensive Small Cell Lung Cancer: A Multicenter, Randomized Clinical Trial by the National Cancer Institute of Canada
Abstract
The National Cancer Institute of Canada Clinical Trials Group conducted a prospective randomized study comparing standard chemotherapy with alternating chemotherapy in patients with extensive small cell lung cancer. "Standard" treatment consisted of cyclophosphamide (1000 mg/m2 body surface area); doxorubicin (50 mg/m2), and vincristine (2 mg) every 3 weeks for six courses. Alternating chemotherapy was cyclophosphamide, doxorubicin, and vincristine alternating with etoposide (100 mg/m2 on days 1 to 3) and cisplatin (25 mg/m2 on days 1 to 3) every 3 weeks for six treatment cycles. Two hundred eighty-nine patients were eligible and evaluable for response to therapy and survival. Best response was higher in patients on alternating chemotherapy (complete plus partial response, 80% compared with 63.2%; p less than 0.002). Progression-free survival for patients on alternating chemotherapy was superior (p less than 0.0001) as was overall survival (p = 0.03). Major toxicities were equally frequent in both treatment groups. These results show a modest superiority of alternating chemotherapy over standard therapy in extensive small cell lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
van Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
Murray, N., Coy, P., Pater, J. L., Hodson, I., Arnold, A., Zee, B. C., Payne, D., Kostashuk, E. C., Evans, W. K., & Dixon, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.2.336 · Cited by 724
Self-citationRoth, B. J., Johnson, D. H., Einhorn, L. H., Schacter, L. P., Cherng, N. C., Cohen, H. J., Crawford, J., Randolph, J. A., Goodlow, J. L., & Broun, G. O. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.282 · Cited by 556
Jackman, D. M., & Johnson, B. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67569-1 · Cited by 503
Sundstrøm, S., Bremnes, R. M., Kaasa, S., Aasebø, U., Hatlevoll, R., Dahle, R., Boye, N., Wang, M., Vigander, T., Vilsvik, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.111 · Cited by 499
Metadata
- Authors
- EVANS, W. K., FELD, R., MURRAY, N., WILLAN, A., OSOBA, D., SHEPHERD, F. A., CLARK, D. A., LEVITT, M., MacDONALD, A., WILSON, K., SHELLEY, W., & PATER, J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1987-10-01
- Volume
- 107
- Issue
- 4
- Pages
- 451-458
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2122995772
- Cited by
- 223
- References
- 0
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Superiority of Alternating Non-Cross-Resistant Chemotherapy in Extensive Small Cell Lung Cancer: A Multicenter, Randomized Clinical Trial by the National Cancer Institute of Canada. https://app.cochat.ai/papers/10.7326/0003-4819-107-4-451
- The paper
- EVANS, W. K., FELD, R., MURRAY, N., WILLAN, A., OSOBA, D., SHEPHERD, F. A., CLARK, D. A., LEVITT, M., MacDONALD, A., WILSON, K., SHELLEY, W., & PATER, J. (1987). Superiority of Alternating Non-Cross-Resistant Chemotherapy in Extensive Small Cell Lung Cancer: A Multicenter, Randomized Clinical Trial by the National Cancer Institute of Canada. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-107-4-451
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.